Financial Snapshot

Revenue
$0.00
TTM
Gross Margin
Net Earnings
-$25.94M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
256.03%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$1.619M
Q3 2024
Cash
Q3 2024
P/E
-1.963
Nov 29, 2024 EST
Free Cash Flow

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019
Revenue $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019
Revenue $0.00 $0.00 $0.00 $0.00 $0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019
Selling, General & Admin $9.070M $7.243M $4.290M $5.563M $5.009M
YoY Change 25.23% 68.84% -22.89% 11.05%
% of Gross Profit
Research & Development $11.11M $8.933M $3.497M $1.412M $1.912M
YoY Change 24.39% 155.47% 147.58% -26.12%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $20.18M $16.18M $7.787M $6.976M $6.921M
YoY Change 24.77% 107.74% 11.63% 0.78%
Operating Profit -$20.18M -$16.18M -$7.787M
YoY Change 24.77% 107.74%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019
Interest Expense $6.863K $6.967K -$1.029M -$26.55K $240.00
YoY Change -1.49% -100.68% 3773.94% -11162.5%
% of Operating Profit
Other Income/Expense, Net $381.9K $412.0K -$1.503M -$19.60K $0.00
YoY Change -7.32% -127.42% 7566.38%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019
Pretax Income -$19.80M -$15.80M -$12.58M -$6.959M -$6.921M
YoY Change 25.32% 25.61% 80.74% 0.55%
Income Tax
% Of Pretax Income
Net Earnings -$19.77M -$15.77M -$12.50M -$6.637M -$6.493M
YoY Change 25.39% 26.12% 88.41% 2.22%
Net Earnings / Revenue
Basic Earnings Per Share -$1.49 -$1.75 -$2.37
Diluted Earnings Per Share -$1.49 -$1.75 -$1.176M -$624.0K -$610.5K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019
Cash & Short-Term Investments $7.151M $10.95M $10.57M $663.5K $1.710M
YoY Change -34.7% 3.56% 1493.81% -61.19%
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets $268.7K $554.3K $98.20K $83.05K $24.96K
YoY Change -51.53% 464.48% 18.24% 232.73%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $7.564M $11.81M $10.67M $746.5K $1.735M
YoY Change -35.94% 10.64% 1329.65% -56.96%
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.800K $214.0K $654.7K
YoY Change -98.69% -67.31%
Total Long-Term Assets $2.800K $214.0K $654.7K $0.00 $0.00
YoY Change -98.69% -67.31%
Total Assets $7.567M $12.02M $11.33M $746.5K $1.735M
YoY Change
Accounts Payable $1.639M $1.166M $960.4K $201.0K $169.2K
YoY Change 40.59% 21.36% 377.76% 18.81%
Accrued Expenses $3.299M $2.103M $1.074M $792.7K $340.00
YoY Change 56.82% 95.79% 35.53% 233041.18%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $21.37K $25.00K
YoY Change -100.0% -14.52%
Long-Term Debt Due $0.00 $10.59K $0.00
YoY Change -100.0%
Total Short-Term Liabilities $4.937M $3.269M $2.146M $1.694M $374.6K
YoY Change 51.03% 52.33% 26.7% 352.18%
Long-Term Debt $0.00 $0.00 $0.00 $431.8K $9.170K
YoY Change -100.0% 4608.83%
Other Long-Term Liabilities $2.152M $245.3K $0.00 $237.3K $26.00K
YoY Change 777.23% -100.0% 812.54%
Total Long-Term Liabilities $2.152M $245.3K $0.00 $669.1K $35.17K
YoY Change 777.23% -100.0% 1802.36%
Total Liabilities $7.089M $3.514M $2.146M $4.083M $1.907M
YoY Change 101.73% 63.76% -47.44% 114.04%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019
Basic Shares Outstanding 13.26M 9.277M 5.278M
Diluted Shares Outstanding 13.26M 9.277M 5.278M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $50.918 Million

About MAIA Biotechnology, Inc.

MAIA Biotechnology, Inc. is a clinical stage biotechnology company that is engaged in the discovery, development and commercialization of therapies targeting cancer. The company is headquartered in Chicago, Illinois and currently employs 13 full-time employees. The company went IPO on 2022-07-28. The firm's THIO (6-thio-dG, 6-thio-2'-deoxyguanosine) is a first-in-class investigational telomere-targeting agent in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The modified nucleotide 6-thio-2-deoxyguanosine (THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment with THIO followed by PD-(L)1 inhibitors resulted in tumor regression in advanced, in vivo cancer models by induction of cancer type-specific immune memory. THIO is being developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

Industry: Pharmaceutical Preparations Peers: ABVC BIOPHARMA, INC. Spyre Therapeutics, Inc. Ainos, Inc. Neurogene Inc. Aravive, Inc. Avalo Therapeutics, Inc. Codiak BioSciences, Inc. Comera Life Sciences Holdings, Inc. Marker Therapeutics, Inc.